Figure 3.
Progression-free survival for A. gemcitabine alone with or without EGFR mutations and B. gemcitabine plus erlotinib with or without EGFR mutations.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.